论文部分内容阅读
目的 观察BVMAP方案治疗难治性非霍奇金淋巴瘤 (NHL)的疗效。方法 采用博莱霉素 10mg/m2 ,肌肉注射 ,第 1,3,5天 ;长春地辛 3mg/m2 ,静脉滴注 ,第 1,8天 ;氨甲喋呤 12 0mg/m2 ,静脉滴注 ,第 1,8天 ;阿糖胞苷 6 0mg/m2 ,静脉滴注 ,第 1～ 5天 ;强的松 (PDN) 30mg/m2 ,口服 ,第 1～ 14天。 2 8天为 1个周期 ,连续用药 2个周期以上评价疗效。结果 全组 30例 ,CR 5例 ,PR 13例 ,NC 10例 ,PD 2例 ,有效率 6 0 %。不良反应主要是白细胞和血小板下降 ,发生率分别为86 .7%和 6 0 .0 %。结论 BVMAP方案治疗难治性NHL疗效满意 ,毒副反应较低 ,安全可靠。
Objective To observe the efficacy of BVMAP in the treatment of refractory non-Hodgkin’s lymphoma (NHL). Methods bleomycin 10mg / m2, intramuscular injection, the first 1,3,5 days; vindesin 3mg / m2, intravenous drip, day 1,8; methotrexate 120mg / m2, intravenous drip, the first , 8 days; cytarabine 60mg / m2, intravenous drip, 1st to 5th days; prednisone (PDN) 30mg / m2, orally, the first to 14 days. 2 8 days for a cycle of continuous medication for more than 2 cycles to evaluate efficacy. Results The whole group of 30 cases, CR 5 cases, PR 13 cases, NC 10 cases, PD 2 cases, the effective rate 60%. Adverse reactions were mainly leukopenia and thrombocytopenia, with rates of 86.7% and 60.0%, respectively. Conclusion The BVMAP regimen is effective in treating refractory NHL with low toxicity and safety.